Cognito Therapeutics announced today that it enrolled the first patient in a biomarker study within its HOPE pivotal trial. HOPE evaluates a novel disease-modifying therapy that elicits gamma-frequency brain activity through non-invasive sensory stimulation. Cambridge, Massachusetts-based Cognito aims to slow the progression of Alzheimer’s disease from the comfort of a patient’s home. This evaluation looks […]
Neuromodulation/Neurostimulation
Boston Scientific has positive spinal cord stimulation data
Boston Scientific announced positive one-year results from a trial evaluating its spinal cord stimulation (SCS) technology. The SOLIS randomized control trial demonstrated sustained pain relief with the WaveWriter Alpha SCS system for treating non-surgical back pain (NSBP). Boston Scientific presented data at the 2024 North American Neuromodulation Society (NANS) meeting in Las Vegas. Dr. James […]
Medtronic has first U.S. implants of its recently approved DBS tech
Doctors have completed the first U.S. implants of the Medtronic Percept RC neurostimulator for deep brain stimulation (DBS). In a LinkedIn post, Medtronic VP and GM for Brain Modulation, Amaza Reitmeier, confirmed the milestone. Percept RC received FDA approval earlier this month, with company officials calling it a “game-changing” device. “I’m delighted to announce the […]
Nevro earns coverage win for spinal cord stimulation
Nevro (NYSE:NVRO) announced that Carelon Healthcare plans to expand its spinal cord stimulation (SCS) coverage. Carelon plans to publish a new interventional pain management policy expanding SCS coverage for painful diabetic neuropathy (PDN). The policy, set to go into effect on April 14, increases PDN patient coverage by nearly 43 million additional lives. Payers that […]
Medtronic has positive spinal cord stimulation data
Medtronic today announced data from two clinical trials supporting its spinal cord stimulation (SCS) technologies. The medtech giant shared data at the North American Neuromodulation Society (NANS) annual meeting in Las Vegas. Results demonstrated the benefits of SCS in patients with chronic low back pain (CLBP) and leg pain. The company also plans to highlight […]
Onward begins neurostim study to address post-spinal cord injury hemodynamic instability
Onward Medical announced today that it began the HemON NL clinical feasibility study to evaluate its ARC-IM neurostimulation therapy. Onward said that, in late 2023, a study participant received the investigational ARC-IM neurostimulator and lead implant. This study aims to assess the safety and effectiveness of the therapy to address hemodynamic instability after spinal cord […]
FDA approves expanded MRI labeling for Abbott Proclaim neurostim
Abbott announced today that the FDA approved expanded MRI labeling for its Proclaim DRG neurostimulation system. Proclaim DRG provides targeted relief for people with complex regional pain syndrome (CRPS) types I and II of the lower limbs. It stimulates the dorsal root ganglion (DRG) clusters of nerve cells found along the spine. Abbott says four […]
FDA clears painful diabetic neuropathy neurostim therapy from Neuralace
Neuralace Medical announced today that it received FDA clearance for its chronic painful diabetic neuropathy (PDN) treatment. San Diego–based Neuralace says this marks the first-ever FDA clearance of a non-invasive, magnetic peripheral nerve stimulation (mPNS) treatment for PDN. The company says its Axon Therapy could offer “new hope” to millions with the condition. Axon Therapy […]
BrainsWay initiates new studies of non-invasive neurostim
BrainsWay (Nasdaq:BWAY) announced plans for two new feasibility trials evaluating its neurostimulation technology. The studies both involve BrainsWay’s patented rotational field TMS (or Deep TMS 360°). The company’s transcranial magnetic stimulation (TMS) method of stimulation enables the activation of more neurons in the brain. With the new rotational field system under evaluation, two orthogonal TMS […]
Nevro announces layoffs
Pain-treatment device company Nevro (NYSE:NVRO) announced that it is letting go of 63 employees, about 5% of its workforce, as part of a restructuring effort. “This restructuring supports our strategy and allows us to focus our investments to further position Nevro for long-term growth and profitability,” Nevro CEO Kevin Thornal said in a news release […]
Cala Health has positive essential tremor treatment data
Cala today announced results from multiple studies supporting positive outcomes for patients using its TAPS therapy for essential tremor (ET). San Mateo, California-based Cala develops multiple devices for treating essential tremor, including the Cala Trio and the kIQ. The company launched the kIQ wrist-worn device last year. They deliver transcutaneous afferent patterned stimulation (TAPS) therapy […]